Budosan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Budosan

This section defines Budosan by its fundamental identity, composition, class, and general purpose, strictly excluding details on specific uses, dosages, safety, or instructions.

Quick Facts Description
Active Ingredient Budesonide
Form Oral capsules, rectal foam, inhalation suspension
Pharmacological Class Glucocorticosteroid (Corticosteroid)
General Purpose Potent anti-inflammatory action
Origin Synthetic compound

Budosan: A Targeted Glucocorticosteroid

Budosan is a prescription medicine containing the potent active ingredient Budesonide, which is classified pharmacologically as a Glucocorticosteroid. This substance is a synthetic compound designed to mimic hormones naturally produced by the body to reduce inflammation. Budesonide is characterized by its design as a locally acting corticosteroid; it exerts its powerful effect directly at the target site while limiting its presence elsewhere in the body. This pharmacological approach is applied in managing conditions characterized by local inflammation. This pharmacological design helps maximize the therapeutic effect in the targeted tissue while reducing the systemic exposure to the drug.

Composition and Specialized Delivery Forms

The medication is available in several forms, including oral capsules and inhalation suspension. The oral form of Budosan uses specialized enteric-coated capsules to ensure targeted delivery. This coating prevents the Budesonide from dissolving prematurely in the stomach, guaranteeing that the active ingredient is released only when it reaches the lower intestinal tract. This controlled release mechanism is crucial to the drug's identity and function, distinguishing it from conventional, systemically absorbed oral steroids.

General Purpose of This Anti-inflammatory Agent

The overarching purpose of Budosan is to provide powerful, localized relief by serving as a highly effective anti-inflammatory agent and by initiating immunomodulation at the site of administration. The medicine acts at a cellular level to suppress the excessive inflammatory and immune responses that lead to tissue swelling, irritation, and redness. By dampening this inflammatory cascade, the formulation generally helps to alleviate persistent tissue irritation and aids in restoring the stability of the affected tissue.

Regulatory References

  1. Budesonide Drug Monograph (NIH/NCBI)

What side effects are possible with Budosan?

Possible Side Effects and Safety Information

The officially documented safety profile of this medicine, containing the Glucocorticosteroid Budesonide, is structured by frequency and organ system to convey established risks. These classifications reflect how government regulatory documents organize and communicate the medicine's safety profile, focusing on established risk categories.


Adverse Reaction Scope

The regulatory labeling categorizes adverse reactions based on their documented incidence. Effects listed as most common (occurring in ge 5% of patients in some trials) include headache, respiratory tract infection, nausea, and back pain. Other common effects involve the gastrointestinal system (e.g., dyspepsia, flatulence) and musculoskeletal system (e.g., arthralgia).

Key System-Organ Classes involved include Infections and Infestations, Gastrointestinal Disorders, Nervous System Disorders, and Endocrine Disorders.


Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources include systemic glucocorticoid effects such as Adrenal Axis Suppression (HPA axis suppression) and Hypercorticism (Cushing's syndrome-like effects), which are associated with chronic use. The medication also carries an officially documented risk of serious infection due to its immunosuppressive nature, including potentially fatal infections like varicella and measles.

Safety constraints require particular attention in specific populations. Use is not recommended in individuals with severe hepatic impairment (Child-Pugh Class C) due to the documented risk of increased systemic exposure. Caution is advised for patients with pre-existing conditions like diabetes mellitus or osteoporosis. Furthermore, co-administration with strong CYP3A4 inhibitors (like certain antifungal agents) must be avoided or monitored closely, as this interaction can lead to a clinically significant increase in systemic Budesonide exposure and heightened risk of hypercorticism.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Budosan overdose is defined by the potential consequences of excessive systemic glucocorticosteroid exposure, typically arising from chronic use at high doses.

Overdose Risk and Manifestations Official Regulatory Statements
Systemic Effects Documented presentations include hypercorticism and clinical signs consistent with Cushingoid features [SmPC/FDA Labeling].
Physiological Impact Excessive exposure may result in Adrenal Axis Suppression (HPA axis suppression), which carries the risk of a severe consequence: acute adrenal suppression [EMA/FDA Labeling].
Vulnerable Populations Patients with moderate to severe Hepatic Impairment are documented to be at an increased risk of hypercorticism due to potential changes in drug metabolism [NIH/DailyMed].

Mandatory Emergency Actions Regulatory authorities mandate that individuals seek immediate medical attention or contact a Poison Control Center right away in all cases of known or suspected overdose. Treatment involves supportive and symptomatic therapy, and no specific antidote is documented. Monitoring for signs of hypercorticism is required when managing excess exposure.

Therapeutic Uses of Budosan

What Budosan Treats: Main Uses and Benefits

This medication is commonly used in conditions where symptoms may intensify temporarily, such as in certain types of Inflammatory Bowel Disease (IBD) like Crohn's disease and ulcerative colitis. It is also considered a relevant therapeutic option for managing the chronic watery diarrhea and abdominal discomfort characteristic of Microscopic Colitis (including Collagenous and Lymphocytic Colitis).

The medication is applied across domains where additional symptomatic support is needed. It helps relieve the burden of symptoms related to physical discomfort and may help patients cope more steadily with symptom fluctuations. It is also relevant for easing symptom clusters that may become intense or disruptive in conditions like asthma and COPD, and may be part of symptomatic management for these respiratory conditions.

“The support provided by this medication helps patients cope more steadily with difficult symptomatic episodes by easing the overall symptom load.”

This support contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Inflammatory Symptoms Budosan is relevant in clinical settings marked by heightened patient distress associated with symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Budosan Use

Official regulatory information defines specific populations that are eligible, restricted, or absolutely prohibited from using Budosan (budesonide oral formulations).

Eligibility scope Regulatory status Condition
Absolute Contraindication Prohibited Hypersensitivity to Budesonide or any excipient [FDA]. Severe Hepatic Impairment (Child-Pugh Class C) [EMA].
Restricted/Conditional Use Caution & Monitoring Moderate Hepatic Impairment (Child-Pugh Class B) [FDA]. Pre-existing conditions like Hypertension, Diabetes Mellitus, Peptic Ulcer, Glaucoma, or Cataracts [DailyMed].
Age Thresholds Established Use Adults. Pediatric patients ge 8 years of age and weighing > 25 kg [DailyMed].
Age Thresholds Not Established Pediatric patients under 8 years of age or weighing le 25 kg [DailyMed].
Physiological Status Restricted Pregnancy (Category C): use only if benefit justifies risk. Lactation: requires decision to discontinue drug or nursing [DailyMed].

The eligibility profile is structured by these classifications. Use is restricted and requires close monitoring for patients being transferred from systemic corticosteroids or those with active or quiescent tuberculosis, fungal, bacterial, systemic viral, or parasitic infections. The regulatory documents define these specific rules to delineate precisely who can and cannot use the medicine.

What should I know about interactions with other medicines?

Budosan's official interaction profile is defined by its primary metabolism via the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administering the medicine with potent CYP3A4 inhibitors, such as ketoconazole or ritonavir, is officially documented to significantly increase the drug's systemic exposure. Regulatory bodies advise that the co-administration of potent inhibitors should generally be avoided. Conversely, co-administration with CYP3A4 inducers, such as carbamazepine, can reduce Budosan’s systemic levels.

Official regulatory labeling also addresses specific ingested products. Consumption of grapefruit or grapefruit juice must be avoided because it inhibits CYP3A4, leading to a documented increase in systemic exposure. Regarding timing, preparations like antacids and cholestyramine must be administered at least two hours apart from Budosan.

A pharmacodynamic interaction is noted with potassium-lowering diuretics and cardiac glycosides due to a potential additive effect on serum potassium levels. Furthermore, official documents note that patients with reduced liver function (hepatic impairment) exhibit increased systemic availability of Budosan, which is why use is not recommended in cases of severe impairment. No drug-drug combination is formally labeled as contraindicated.

Mechanism of Action

How Budosan Works: Mechanism of Action

Budosan, a highly lipophilic compound, exerts its primary action by functioning as an agonist for the ubiquitous intracellular Glucocorticoid Receptors (GRs). After passive diffusion into the cell cytoplasm, Budosan binds to the inactive GR. This complex subsequently translocates to the cell nucleus, initiating the downstream mechanistic cascade.

Once nuclear access is gained, the primary molecular effect is transrepression. The Budosan-GR complex physically interacts with and inhibits key pro-inflammatory transcription factors, notably NF-kappaB and AP-1. This interaction suppresses the gene transcription that drives the production of numerous inflammatory mediators, including cytokines and chemokines.

This molecular suppression leads to a cellular effect of immunomodulation. The mechanism limits the activation and migration of inflammatory cells (e.g., T-cells, eosinophils) to the target tissue and reduces vascular permeability. The resulting physiological consequence is a reduction in inflammation and associated tissue edema, which modulates tissue hyperreactivity.

Dosage and Administration Information

How Budosan is Used: Standard Administration Guidelines

Budosan (budesonide) administration is defined by specialized dosage forms and specific scheduling to ensure localized delivery. Correct use depends on the route, dose, frequency, and adherence to specific intake constraints.


Administration Routes and Standard Regimens

The medicine is administered via oral capsules, rectal foam, or inhalation suspension, depending on the targeted site of inflammation. Oral delayed-release capsules for gastrointestinal conditions are typically prescribed for a defined treatment course, such as an 8-week induction period at 9 mg once daily in the morning, followed by a potential maintenance dose of 6 mg once daily for up to 3 months. For inhalation, dosing is often administered once or twice daily and adjusted to the lowest dose required to maintain control.


Procedural and Time Constraints

The specialized nature of Budosan requires strict adherence to preparation and intake rules. Oral delayed-release capsules and extended-release tablets must be swallowed whole and not chewed, crushed, or broken, as this will disrupt the targeted intestinal delivery mechanism.

The capsules are consistently taken once daily in the morning. In addition, it is recommended to avoid consumption of grapefruit or grapefruit juice throughout oral therapy due to its potential effect on drug exposure. If a dose is missed, standard practice is to take the next scheduled dose at the usual time and not to take a double dose to compensate.


Course Duration and Tapering

Use is generally limited to defined periods to address active episodes. Upon the end of a treatment course, the protocol involves a gradual reduction in dosage (tapering), such as reducing from 9 mg to 6 mg daily, to allow the body to adjust before full discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Budosan

This overview summarizes the key findings from official research, including randomized controlled trials (RCTs) and systematic reviews, regarding the clinical evaluation of Budosan (Budesonide). This overview describes the types of research and outcomes that studies have explored.


Evidence for Use in Inflammatory Bowel Disease (IBD)

Research for the oral and rectal forms was studied using specific formulations for use in the lower gastrointestinal tract. Research for Budosan was studied in conditions like Inflammatory Bowel Disease (IBD), which are characterized by fluctuating or episodic manifestations.

  • Active Mild-to-Moderate Crohn's Disease: These studies were used in research examining how symptoms evolved in the observed populations, specifically for participants whose inflammation was confined to the ileum and/or right colon. Trials reported that findings describe patterns observed in the studies over the short-term induction period (8 to 16 weeks). Research indicates that the reported measurements of clinical remission were distinct from patterns observed in studies of conventional systemic steroids.

  • Active Mild-to-Moderate Ulcerative Colitis (UC): The research examined outcomes such as achieving clinical and endoscopic remission after defined periods. Research describes that comparative evidence against the full range of active agents used in UC is lacking, and the reported outcomes were observed to be distinct from patterns described for some other therapies.


Evidence for Use in Microscopic Colitis

Budosan has been extensively evaluated in adults, often including older adults, with Microscopic Colitis (Collagenous and Lymphocytic Colitis). Research consistently describes that a pattern of clinical remission (the resolution of chronic watery diarrhea) was observed in participants after induction treatment courses. However, clinical studies monitored high rates of symptom recurrence following the discontinuation of the treatment.


Evidence for Use in Chronic Respiratory Conditions

In its inhaled form, Budosan was studied for its use in long-term management for persistent asthma and moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). In asthma, research contributes to understanding symptom patterns, including data show patterns related to measured changes in exacerbation frequency and outcomes reflecting lung function. In COPD, research has primarily examined Budosan when used in combination with other respiratory medicines, focusing on outcomes linked to inflammatory or irritative states.


Research Limitations and Uncertainty

The research shows that long-term effects are not fully established; research for extended outcomes is ongoing. Study results apply primarily to specific populations and disease extents, and data for certain groups remain insufficient for patients with more extensive disease in Crohn's. The documentation of high relapse rates in Microscopic Colitis means the sustained outcome after discontinuing the medicine appears to be uncertain.

Frequently Asked Questions (FAQ)

Common questions about Budosan (FAQ)


Q: What is the main difference between Budosan and [Similar Drug Name]?

Budosan is a glucocorticosteroid that is designed to act locally at the site of inflammation, such as in the gut or lungs. Official documents state that this targeted approach is intended to result in less systemic absorption of the drug compared to conventional oral steroids. This difference in design is a key feature of its pharmacological identity.


Q: How quickly does Budosan start working for the stated condition?

Clinical studies for the oral formulation typically examine patterns of improvement and clinical remission over defined induction periods. For example, research for some inflammatory conditions evaluates outcomes after an 8-week course. Therefore, official information describes the measured effects as occurring within these specific time frames.


Q: Does Budosan interact with common pain relievers like Tylenol (acetaminophen)?

Official drug labels list known major and moderate drug interactions, particularly those involving the CYP3A4 enzyme system. While common pain relievers like acetaminophen are not universally listed as interacting, regulatory documents indicate that patients should discuss all concurrent medications, including over-the-counter products, with their healthcare provider.


Q: Can Budosan affect my sleep or cause insomnia?

Insomnia, which involves difficulty falling asleep or staying asleep, is a potential side effect listed in official regulatory documents based on reports from clinical trials for oral Budosan. A healthcare provider should be consulted if persistent or severe changes in sleep patterns are experienced.


Q: Can I take other vitamins or supplements while on Budosan?

The official product information states that Budosan is metabolized by an enzyme in the liver called CYP3A4. For this reason, certain supplements, including herbal products, that affect this enzyme can potentially change the level of Budosan in the body. Furthermore, specific timing constraints exist for administering the medicine alongside certain products like antacids.


Q: Does Budosan make you gain weight?

Systemic side effects, such as Cushing's syndrome-like effects, are documented as serious risks, especially with high doses or long-term use. Official documents state that these effects can involve features like weight gain concentrated in the upper body and a puffy appearance of the face. The medicine’s localized action is designed to minimize the possibility of these systemic effects.


Q: Can older adults (seniors) use Budosan safely?

Use of Budosan is established for adults generally, and the medicine was evaluated in studies involving older participants for conditions like Microscopic Colitis. However, official guidance advises caution for patients of all ages with pre-existing conditions common in seniors, such as diabetes and osteoporosis. A healthcare provider will determine appropriateness based on an individual's overall health profile.


Q: Can Budosan cause mood changes or depression?

Mood changes are reported as a potential side effect in official documents for Budosan. Severe changes in mood can also be a sign of adrenal insufficiency, a serious condition documented as a risk of chronic use. Any unexpected mental or emotional changes should be discussed with a healthcare provider.


Q: Is Budosan considered a high-risk medication?

The official documentation of Budosan outlines warnings and precautions due to the potential for serious adverse reactions. These include the potential for adrenal axis suppression and an increased risk of serious infection. These facts indicate that the medication requires careful use and monitoring by a healthcare professional, especially when used long-term.


Q: Does the efficacy of Budosan decrease over time?

Clinical research has noted patterns of high symptom recurrence (relapse) in participants following the discontinuation of treatment for conditions like Microscopic Colitis. Furthermore, official research documents state that the long-term effects of the medicine are not yet fully established. This suggests that sustained benefit may vary, and monitoring is necessary.


Q: Can Budosan be used for conditions other than the ones listed in the official documents?

According to the official product information, the medicine is only indicated for the specific conditions approved by regulatory bodies in your region. These may include mild-to-moderate active Crohn's disease, ulcerative colitis, or specific respiratory conditions, depending on the formulation. Official documents do not support the use of Budosan for unlisted conditions.


Q: Is there a generic version of Budosan available?

Yes, the active ingredient in Budosan, budesonide, is available as a generic drug under its common name. Generic versions are approved by regulatory bodies to be therapeutically equivalent to the brand-name product. This means they are expected to work in the body in the same way.


Q: Do the side effects of Budosan usually go away after a few days?

Some common adverse effects listed in official documents may be temporary and resolve after a few days or weeks as the body adjusts to the medicine. However, if any side effect persists, worsens, or becomes severe, a healthcare professional should be consulted promptly.


Q: Is Budosan typically covered by insurance?

Official information regarding coverage indicates that insurance plans vary widely in terms of what they cover and the level of cost. For brand-name products, assistance programs or copay offers may be available through the manufacturer for eligible, commercially insured patients.


Q: Is it safe to drive or operate machinery after taking Budosan?

Official regulatory labels do not usually include a specific warning against driving or operating machinery while taking Budosan. However, official guidance states that if you experience side effects that could affect your ability to think or move, caution should be exercised.


Q: How is Budosan eliminated from the body?

Budosan (budesonide) is primarily and quickly broken down in the liver by the CYP3A4 enzyme system. The resulting breakdown products (metabolites) have low anti-inflammatory activity and are then mostly eliminated from the body through the urine.


Q: Are there specific symptoms that mean I should call a doctor while taking Budosan?

Official patient information documents state that certain severe symptoms warrant immediate medical attention. These include signs of a severe allergic reaction, such as difficulty breathing or swelling of the face, or symptoms consistent with adrenal insufficiency, such as severe vomiting or unusual muscle weakness.


Q: Is it normal to feel tired when first starting Budosan?

Fatigue and a general feeling of being very tired are listed as potential side effects of the oral form of budesonide reported in clinical studies. Medical guidance should be sought if this feeling of tiredness is severe or interferes with daily life.


Q: Is Budosan known to cause thinning of the skin?

Skin and subcutaneous disorders were reported in a significant percentage of subjects in clinical studies for Budosan. While thinning of the skin is a known risk associated with systemic corticosteroids, the targeted delivery of Budosan aims to limit the systemic presence of the drug to reduce this particular risk.


Q: Can I drink alcohol moderately while taking Budosan?

Official drug and food interaction information notes a documented interaction with budesonide. Regulatory advice indicates that a prescribing healthcare professional should be consulted for guidance regarding the appropriateness of consuming alcohol.


Q: Is Budosan a biological medicine?

No, Budosan, which contains the active ingredient budesonide, is not classified as a biological medicine. It is a synthetic chemical compound that belongs to the pharmacological class of nonhalogenated glucocorticoids (corticosteroids).


Q: Why do some patients have to take Budosan with food?

Instructions regarding food intake vary depending on the specific formulation of Budosan being used. For example, some specialized oral capsules are instructed to be taken at least one hour before a meal, while others may be taken regardless of food. Adherence to the instructions provided with the specific dosage form is necessary for correct use.


Q: Can Budosan cause a metallic taste in the mouth?

Taste disturbance (known clinically as dysgeusia), which can be described as a metallic or unpleasant taste, is registered in official regulatory documents as a potential adverse effect for some budesonide formulations. This disturbance can manifest as a metallic or otherwise unpleasant taste.


Q: Are there any laboratory tests required before starting Budosan?

While official regulatory documents do not mandate specific, universal pre-treatment lab tests, certain monitoring is advised during therapy. Because the medicine carries a risk of effects like adrenal suppression or changes in blood sugar, laboratory work may be required for monitoring during treatment, particularly for high-risk patients.


Q: Is Budosan a controlled substance?

No, budesonide is not classified as a controlled substance under the United States Controlled Substances Act or similar international regulatory schedules. It does not possess characteristics that would place it under these special regulatory controls.


Q: Are there patient assistance programs available for Budosan?

Yes, specific patient support or assistance programs, including copay offers, may be available from the brand-name manufacturer of Budosan. Official guidance directs that eligibility and benefits for these programs are dependent on the patient's individual circumstances and insurance status.


Q: What official body first approved Budosan for use?

The active ingredient budesonide has been approved for its various uses and dosage forms by multiple major international regulatory bodies. Official approval history shows that major agencies like the US FDA and the European Medicines Agency (EMA) have authorized specific brand-name formulations at various times for different indications.


How should Budosan be stored and disposed of?

How to Store and Dispose of Budesonide (Budosan)

The storage and disposal requirements for Budesonide are strictly defined by regulatory documents to maintain product integrity and safety.

Storage Conditions and Handling

The medication must be stored at Controlled Room Temperature, which is defined as 20°C to 25°C (68 F to 77 F). The medicine must be protected from excess heat and moisture, and storage areas like bathrooms are prohibited.

The product must remain in its original container, kept tightly closed to maintain its stability.

Child Safety and Disposal

For child protection, Budesonide must be stored out of sight and reach of children in a safe, up and away location, and safety caps must be locked. Unused or expired medication must be disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Budosan found in:

A-Z Index: